Maxim Group analyst Jason McCarthy maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price target from $4 to $10.
- Company Dashboard
- Filings
- Patents
-
Article
Maxim Group Maintains Buy on Context Therapeutics, Raises Price Target to $10
Company Profile